ClinicalTrials.gg
CompletedNCT06083623Updated Mar 5, 2026

A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants

A Phase 2/3 interventional study of TNM001 and placebo in Respiratory Syncytial Virus Infections, sponsored by Zhuhai Trinomab Pharmaceutical Co., Ltd.. Completed at 39 sites in China. Open to participants aged 0 Years to 1 Year, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Zhuhai Trinomab Pharmaceutical Co., Ltd. · Phase 2/3, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
2,282
Allocation
Randomized
Ages
0 Years to 1 Year
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies in Respiratory Syncytial Virus Infections with a site in China — 8 open to participants now, 13 under way, 4 of them phase 3. Respiratory Syncytial Virus Infections · China.

Enrollment
3rd of 25
2,282 · median 132
Started
2023
with 6 others
Phase 2/3
4 of 30
1 open now
Registered
11th of 30
by date
Lead sponsor
3 of 30
Zhuhai Trinomab Pharmaceutical Co., Ltd.

Among the 30 studies in Respiratory Syncytial Virus Infections with a site in China, this one is the 3rd largest by enrollment of the 25 interventional ones that give a count, is one of 7 that started in 2023, is one of 4 in phase 2/3, and was the 11th registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

8 of the 30 studies in Respiratory Syncytial Virus Infections with a site in China are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 0 Years to 1 Year · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Respiratory Syncytial Virus Infections with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), neutralizing antibody and antidrug antibody (ADA) response for TNM001 in infants entering their first RSV season.

Read the detailed description

This study adopts an adaptive seamless dose selection design and consists of two parts: Part 1 is a phase 2b dose ranging trial which will support to determine the dose for Part 2, the phase 3 trial. The study population includes early and mid-term preterm infants [gestational age (GA)﹤35 weeks 0 day] and late preterm infants or full-term infants (≥35 weeks 0 day GA), with or without Congenital Heart Disease (CHD) or premature infants Chronic Lung Disease (CLD). A total of approximately 2250 infants will be randomized 2:1 to receive either TNM001 or placebo. All subjects will be followed for 240 days after dosing. This study will be conducted in appropriately 50 sites in China.

03

Conditions studied

  • Respiratory Syncytial Virus Infections
04

Who can participate

Ages eligible
0 Years to 1 Year
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Early and mid-term preterm infants (\<35 weeks 0 day GA) and late preterm infants or full-term infants (≥35 weeks 0 day GA) under 1 year of age, with or without Congenital Heart Disease (CHD) or premature infants Chronic Lung Disease (CLD),who are entering their first RSV season at the time of screening.

Exclusion criteria

Exclusion Criteria:

  • 1. Any fever (> 38.0°C) or acute illness within 7 days prior to randomization
  • 2. History of RSV infection or active RSV infection prior to, or at the time of, randomization
  • 3. Drug medication prior to randomization or expected to be treated by medicines during the study period.
  • 4. Currently receiving or expected to receive therapy during the study period.
  • 5. Renal impairment or hepatic dysfunction
  • 6. Nervous system disease or neuromuscular disease
  • 7. Prior history of a suspected or actual acute life-threatening event
  • 8. Known immunodeficiency including , mother with HIV infection unless the child's infection has been excluded.
  • 9. Known allergy history of immunoglobulin products, receipt or expected to receive immunoglobulins or blood products during the study period.
  • 10.Receipt of RSV vaccine or mAb
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,282 participants (actual)

Study arms

  • Experimental
    TNM001

    Biological: TNM001

  • Placebo comparator
    Placebo

    Biological: placebo

Interventions

  • BiologicalTNM001

    single dose intramuscular injection

  • Biologicalplacebo

    single dose intramuscular injection

06

What researchers measure

Primary outcomes

  1. Incidence of medically attended LRTI due to RT-PCR confirmed RSV

    Time frame: 150 days post dose

Secondary outcomes

  1. Incidence of hospitalization due to RT-PCR confirmed RSV LRTI

    Time frame: 150 days post dose

  2. Occurrence of adverse events (AEs)

    Time frame: 240 days post dose

  3. Change in body temperature (celsius)

    Time frame: 240 days post dose

  4. Change in blood pressure (mmHg)

    Time frame: 240 days post dose

  5. Change in heart rate (beats per minute)

    Time frame: 240 days post dose

  6. Change in respiratory rate (breaths per min)

    Time frame: 240 days post dose

  7. Number of subjects with clinical significant abnormality in physical examinations

    Time frame: 240 days post dose

  8. Serum concentration of single dose TNM001 at pre-specified timepoints

    Time frame: 240 days post dose

  9. Serum level of neutralizing antibody to RSV

    Time frame: 240 days post dose

  10. Positive rate of anti-drug antibody (ADA) to TNM001 in serum

    Time frame: 240 days post dose

07

Study locations

39 sites
  • Peking University Third Hospital
    Beijing, Beijing Municipality 100000, China
  • Children's Hospital Capital Institute Pediatrics
    Beijing, Beijing Municipality 100020, China
  • Jiangjin Central Hospital
    Chongqing, Chongqing Municipality 400000, China
  • Xiamen maternal and Child Health Hospital
    Xiamen, Fujian 361003, China
  • The Third Affiliated Hospital of Guangzhou Medical University
    Guangdong, Guangdong 510150, China
  • Guangdong Maternal and Child Health Care Hospital
    Guangzhou, Guangdong 511442, China
  • University of Chinese Academy of Sciense Shenzhen Hospital
    Shenzhen, Guangdong 518000, China
  • Affiliated Hospital of Guilin Medical University
    Guilin, Guangxi 541001, China
  • LiuZhou People's Hospital
    Liuzhou, Guangxi 545006, China
  • Maternity and Child Health Care of Guangxi Zhuang Autonomous Region
    Nanning, Guangxi 530002, China
  • HaiNan Women and Children's Medical Center
    Haikou, Hainan 570312, China
  • Hebei Petro China Central Hospital
    Langfang, Hebei 065000, China
  • The Fourth Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
  • The Second Hospital of HeBei Medical University (HBMU)
    Shijiazhuang, Hebei 050000, China
  • Tangshan Maternal and Child Health Hospitaltangshan Maternal and Child Health Hospital
    Tangshan, Hebei 063000, China
  • Sanmenxia Central Hospital
    Sanmenxia, Henan 472000, China
  • Xinxiang First People's Hospital
    Xinxiang, Henan 453000, China
  • Henan (Zhengzhou) Children's Hospital
    Zhengzhou, Henan 450052, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
  • The Central Hospital of Wuhan
    Wuhan, Hubei 430060, China
  • The First People'S Hospital of Changde City
    Changde, Hunan 415000, China
  • The Maternal and Child Health Hospital of Hunan Province
    Changsha, Hunan 410008, China
  • Xiangya Hospital Central South University
    Changsha, Hunan 410008, China
  • The Third Xiangya Hospital of Central South University
    Changsha, Hunan 410013, China
  • The Second Hospital University of South China
    Hengyang, Hunan 421001, China
  • Loudi Central Hospital
    Loudi, Hunan 417099, China
  • The First Affiliated Hospital of Shaoyang University
    Shaoyang, Hunan 422000, China
  • Jiangxi Maternal and Child Health Hospital
    Nanchang, Jiangxi 330000, China
  • Children's Hospital Affiliated to Shandong University
    Jinan, Shandong 250022, China
  • The affiliated children'shospital fudan university
    Shanghai, Shanghai Municipality 201102, China
  • Linfen Central Hospital
    Linfen, Shanxi 041000, China
  • Linfen People's Hospital
    Linfen, Shanxi 041000, China
  • Yuncheng Central Hospital
    Yuncheng, Shanxi 044000, China
  • Chengdu Women's and Children's Central Hospital
    Chengdu, Sichuan 610000, China
  • West China Second University Hospital, Sichuan University
    Chengdu, Sichuan 610000, China
  • Children's Hospital of Chongqing Medical University
    Chongqing, Sichuan 404100, China
  • Mianyang Peoples Hospital
    Mianyang, Sichuan 621000, China
  • Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine/Hangzhou First People's Hospital
    Hangzhou, Zhejiang 310006, China
  • Ningbo Women&Children's Hospital
    Ningbo, Zhejiang 315012, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Jun 2025, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2023
First posted
Oct 16, 2023
StartActual
Sep 11, 2023
Primary completionActual
Jun 16, 2025
CompletionActual
Nov 5, 2025
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06083623
Lead sponsor
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Oct 16, 2023
Start date
Sep 11, 2023
Primary completion
Jun 16, 2025
Completion
Nov 5, 2025
Last update
Mar 5, 2026

Study contacts

Hanmin Liu, MD
principal investigator · West China Second Hospital, Sichuan University
Enmei Liu, MD
principal investigator · Children's Hospital of Chongqing Medical University
Ying Wang
study director · Zhuhai Trinomab Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retavibart

Start the discussion